Optimal Asset Management’s AstraZeneca AZN Stock Holding History

Optimal Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.13M	Buy	+17,751	New	+$2.07M	0.27%	140

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Optimal Asset Management's AZN Position: Q3 2021 in Review

Optimal Asset Management opened a new position in AstraZeneca (AZN) in Q3 2021: 17,751 shares worth $2.13M. The stake represents 0.27% of the portfolio and ranks #140 among its holdings.

905 funds tracked by Wall St. Rank hold AZN as of Q3 2021.

Optimal Asset Management held 17,751 shares of AstraZeneca worth $2.13M as of Q3 2021.
AstraZeneca was a new Optimal Asset Management position in Q3 2021.
AstraZeneca made up 0.27% of Optimal Asset Management's portfolio in Q3 2021, its #140 holding.
905 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2021.

Based on Optimal Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.